Chromatin Modifying Enzyme Inhibition for Stem Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing induced pluripotent stem cells are inefficient and can lead to oncogene upregulation, increasing the risk of tumor formation due to the use of multiple transcription factors with unwanted side effects.
Innovation Solution
Inhibiting Dot1L, YY1, and SUV39H1 enzymes during the reprogramming process to enhance efficiency and reduce the number of transcription factors required, using enzyme inhibitors or RNAi molecules to knock down their expression, and culturing cells under specific reprogramming conditions with a cocktail containing Oct4 and Sox2, potentially omitting Klf4 and c-Myc.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If multiple transcription factors (including Klf4 and c-Myc) are used for reprogramming, then reprogramming efficiency is improved, but the risk of oncogene upregulation and tumor formation increases
Solution Approach 1:
The patent extracts and removes the harmful transcription factors Klf4 and c-Myc from the reprogramming cocktail while retaining the essential factors Oct4 and Sox2. This selective removal eliminates the oncogenic risk associated with Klf4 and c-Myc while maintaining reprogramming functionality through the action of Dot1L inhibitor and YY1 inhibitor that compensate for their absence.
Solution Approach 2:
The patent converts the harmful effect of Dot1L and YY1 (which maintain differentiated state and inhibit reprogramming) into a benefit by using specific inhibitors against these enzymes. The Dot1L inhibitor and YY1 inhibitor transform these obstacles into facilitators of reprogramming, enabling efficient differentiation without requiring oncogenic transcription factors.
2Productivity
If conventional reprogramming methods are used, then stem cells can be produced, but the process is time-consuming and inefficient
Solution Approach 1:
The patent applies preliminary inhibition of Dot1L and YY1 enzymes before initiating the reprogramming process with Oct4 and Sox2. This pre-treatment prepares the cellular environment by removing epigenetic barriers in advance, allowing the reprogramming to proceed more rapidly and efficiently without the time delays associated with conventional methods.
Solution Approach 2:
The patent changes the biochemical parameters of the reprogramming system by introducing Dot1L inhibitor and YY1 inhibitor at specific concentrations and timing. These parameter modifications create optimal conditions for rapid reprogramming, reducing the time required for cellular differentiation while maintaining high efficiency through controlled enzymatic inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach accelerates and simplifies the reprogramming process, reducing the risk of oncogenesis by using fewer oncogenic transcription factors and increasing the yield of induced pluripotent stem cells, allowing for more efficient production of pluripotent stem cells that can differentiate into various cell types.
Implementation Method 1
inhibiting Dot1L (a histone H3 methyltransferase), and one or more of YY1 (a transcriptional repressor protein), and/or SUV39H1 (a histone-lysine N-methyltransferase) helps promote the reprogramming of differentiated cells
Implementation Method 2
Knock down of Dot1L, YY1, and/or SUV39H1 expression in a differentiated cell can be achieved by any appropriate technique, including, for example, by using RNAi (e.g., siRNA, shRNA) molecules
Data Source
Figure 1A~1D
Figure 2B~2E
Figure 3A~3E
AI summary
Methods and compositions are provided for the production of stem cells and induced pluripotent stem cells, and for uses thereof.